• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EULAR 大数据在风湿和肌肉骨骼疾病中的应用要点。

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.

机构信息

Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France

APHP, Rheumatology Department, Pitie Salpetriere Hospital, Paris, France.

出版信息

Ann Rheum Dis. 2020 Jan;79(1):69-76. doi: 10.1136/annrheumdis-2019-215694. Epub 2019 Jun 22.

DOI:10.1136/annrheumdis-2019-215694
PMID:31229952
Abstract

BACKGROUND

Tremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs).

METHODS

A multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated.

RESULTS

Three overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice.

CONCLUSION

These EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.

摘要

背景

大数据和人工智能的最近扩展为健康研究带来了巨大的机会。然而,这是一个新兴领域,需要提出最佳使用和实施的建议。这些欧洲抗风湿病联盟(EULAR)需要考虑的要点旨在指导在风湿和肌肉骨骼疾病(RMD)中大数据的收集、分析和使用。

方法

一个由 14 名国际专家组成的多学科工作组,具有计算机科学和人工智能等一系列学科的专业知识。根据对 RMD 中大数据和其他医学领域的现状的文献回顾,制定了需要考虑的要点。分配了证据水平和建议强度,并计算了工作组成员的平均一致性水平。

结果

制定了三个总体原则和 10 个需要考虑的要点。这些总体原则涉及处理 RMD 中大数据的道德和一般原则。这些要点涵盖了数据源和数据收集、隐私设计、数据平台、数据共享和数据分析等方面,特别是通过人工智能和机器学习。此外,这些要点指出大数据是一个不断发展的领域,需要充分报告方法和基准测试,仔细解释数据并在临床实践中实施。

结论

这些 EULAR 需要考虑的要点讨论了基本问题,并为 RMD 中的大数据提供了一个框架。

相似文献

1
EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.EULAR 大数据在风湿和肌肉骨骼疾病中的应用要点。
Ann Rheum Dis. 2020 Jan;79(1):69-76. doi: 10.1136/annrheumdis-2019-215694. Epub 2019 Jun 22.
2
Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.大数据和人工智能在 RMDs 中的使用现状:系统文献回顾为 EULAR 推荐提供信息。
RMD Open. 2019 Jul 18;5(2):e001004. doi: 10.1136/rmdopen-2019-001004. eCollection 2019.
3
Big data and data processing in rheumatology: bioethical perspectives.大数据与风湿病学的数据处理:生物伦理视角。
Clin Rheumatol. 2020 Apr;39(4):1007-1014. doi: 10.1007/s10067-020-04969-w. Epub 2020 Feb 15.
4
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.欧洲抗风湿病联盟关于炎症性风湿和肌肉骨骼疾病生物制药治疗药物监测的考虑要点
Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12.
5
EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs).EULAR 提出的在风湿和肌肉骨骼疾病(RMDs)患者中使用影像学引导介入治疗时需要考虑的问题。
Ann Rheum Dis. 2022 Jun;81(6):760-767. doi: 10.1136/annrheumdis-2021-221261. Epub 2021 Dec 10.
6
EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.EULAR 发布移动医疗应用程序开发、评估和实施的相关考量,以辅助风湿和肌肉骨骼疾病患者的自我管理。
RMD Open. 2019 Sep 13;5(2):e001014. doi: 10.1136/rmdopen-2019-001014. eCollection 2019.
7
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).风湿和肌肉骨骼疾病(RMDs)术语的通用语言描述,用于与普通公众、医疗保健提供者和其他利益相关者进行沟通,该描述得到了欧洲抗风湿病联盟(EULAR)和美国风湿病学会(ACR)的认可。
Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13.
8
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.2021年欧洲抗风湿病联盟关于生活方式行为及工作参与以预防风湿性和肌肉骨骼疾病进展的建议。
Ann Rheum Dis. 2023 Jan;82(1):48-56. doi: 10.1136/annrheumdis-2021-222020. Epub 2022 Mar 8.
9
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).风湿和肌肉骨骼疾病(RMDs)术语的通用语言描述,用于与普通公众、医疗保健提供者和其他利益相关者进行沟通,该描述得到了欧洲抗风湿病联盟(EULAR)和美国风湿病学会(ACR)的认可。
Ann Rheum Dis. 2018 Jun;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565. Epub 2018 Mar 13.
10
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs).EULAR 关于在风湿和肌肉骨骼疾病(RMDs)中报告超声研究的建议。
Ann Rheum Dis. 2021 Jul;80(7):840-847. doi: 10.1136/annrheumdis-2020-219816. Epub 2021 Jan 22.

引用本文的文献

1
Bioethical Considerations of Deploying Artificial Intelligence in Clinical Orthopedic Settings: A Narrative Review.在临床骨科环境中部署人工智能的生物伦理考量:一项叙述性综述。
HSS J. 2025 May 30:15563316251340303. doi: 10.1177/15563316251340303.
2
Artificial intelligence in rheumatology: status quo and quo vadis-results of a national survey among German rheumatologists.风湿病学中的人工智能:现状与未来发展——德国风湿病学家全国性调查结果
Ther Adv Musculoskelet Dis. 2024 Nov 14;16:1759720X241275818. doi: 10.1177/1759720X241275818. eCollection 2024.
3
Vignette-based comparative analysis of ChatGPT and specialist treatment decisions for rheumatic patients: results of the Rheum2Guide study.
基于病例的 ChatGPT 与风湿病专家治疗决策的比较分析:Rheum2Guide 研究结果。
Rheumatol Int. 2024 Oct;44(10):2043-2053. doi: 10.1007/s00296-024-05675-5. Epub 2024 Aug 10.
4
The emerging paradigm in pediatric rheumatology: harnessing the power of artificial intelligence.儿科风湿病学的新兴范例:利用人工智能的力量。
Rheumatol Int. 2024 Nov;44(11):2315-2325. doi: 10.1007/s00296-024-05661-x. Epub 2024 Jul 16.
5
Rheumatoid arthritis patients' perspective on the use of prediction models in clinical decision-making.类风湿关节炎患者对预测模型在临床决策中应用的看法。
Rheumatology (Oxford). 2025 Mar 1;64(3):1045-1051. doi: 10.1093/rheumatology/keae202.
6
Systemic lupus in the era of machine learning medicine.机器学习医学时代的系统性红斑狼疮。
Lupus Sci Med. 2024 Mar 4;11(1):e001140. doi: 10.1136/lupus-2023-001140.
7
Entry point of machine learning in axial spondyloarthritis.机器学习在中轴型脊柱关节炎中的切入点。
RMD Open. 2024 Feb 15;10(1):e003832. doi: 10.1136/rmdopen-2023-003832.
8
Artificial intelligence in rheumatoid arthritis: potential applications and future implications.类风湿关节炎中的人工智能:潜在应用与未来影响。
Front Med (Lausanne). 2023 Nov 16;10:1280312. doi: 10.3389/fmed.2023.1280312. eCollection 2023.
9
Narrative Review of Machine Learning in Rheumatic and Musculoskeletal Diseases for Clinicians and Researchers: Biases, Goals, and Future Directions.机器学习在风湿和肌肉骨骼疾病中的临床应用和研究的叙述性综述:偏倚、目标和未来方向。
J Rheumatol. 2022 Nov;49(11):1191-1200. doi: 10.3899/jrheum.220326. Epub 2022 Jul 15.
10
Digitalization and disruptive change in rheumatology.风湿病学的数字化和颠覆性变革。
Z Rheumatol. 2023 Jun;82(5):417-424. doi: 10.1007/s00393-022-01222-4. Epub 2022 May 31.